Caladrius Biosciences Inc., of Basking Ridge, N.J., said it entered definitive agreements with several institutional and accredited investors for the sale of 2.16 million shares at $2.3125 each, in a registered direct offering priced at-the-market under Nasdaq rules. It has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1.08 million shares of common stock. The company intends to use the net proceeds for working capital and general corporate purposes.
Lineage Cell Therapeutics Inc., of Carlsbad, Calif., said it priced 1.67 million shares of Oncocyte Corp., of Irvine, Calif., at $2.27 per share, for net proceeds of approximately $3.7 million. Lineage will own approximately 4.3 million shares of Oncocyte, a molecular diagnostics company, following the close of the transaction.
Pluristem Therapeutics Inc., of Haifa, Israel, said the European Investment Bank has approved a €50 million (US$54 million) nondilutive financing that will support the company’s research and development in the EU, the advancement of its regenerative cell therapy platform, and the product pipeline, with a special focus on clinical development of PLX cells as a treatment for complications associated with COVID-19. The financing will be available in three tranches, subject to the achievement of certain clinical, regulatory and scaling-up milestones, with the first tranche consisting of €20 million.